Navigation Links
Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
Date:11/3/2010

NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.  The Company intends to use the proceeds from these financings for general corporate purposes, including working capital, and to fund development activities for its lead product candidate, CNDO-109, including the initiation of a Phase 2 clinical trial in the US in patients with advanced acute myelogeous leukemia (AML).  Paramount BioCapital, Inc. acted as lead placement agent for the financings.

CNDO-109 is a biological product based on in-licensed technology that activates natural killer (NK) cells harvested from close relatives of cancer patients or from the patient  for the therapy of a wide-range of difficult to treat blood and solid tumor cancers.

Based on the results of a recently-completed Phase 1 open-label, uncontrolled clinical trial of CNDO-109 therapy in adult AML patients conducted at the Royal Free Hospital in London, the Company intends to file a Investigational New Drug application (IND) with the US Food and Drug Administration and to pursue a multicenter Phase 2 clinical trial for AML patients in the US, which the Company expects to commence in 2011.

Glenn L. Cooper, MD has joined the Company as Executive Chairman and Acting Chief Executive Officer, replacing R.J. Tesi, M.D., who has left the Company.  Dr. Cooper has 20 years of experience in the pharmaceutical and biotechnology industries, most recently as Chairman and Chief Executive Officer of Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009 for an aggregate acquisition price that has the potential to reach $700 million.

Eric Rowinsky, MD, has joined the Company as Vice Chairman and will serve as a consultant with particular focus on oversight of the Company's clinical development programs. Dr. Rowinsky was Chief Medical Officer and Executive Vice President at Imclone Systems from 2005 to 2009. Dr. Rowinsky is one of the country's leading cancer drug development experts.

Gary Gemignani has joined the company as Executive Vice President, Chief Operating Officer and Chief Financial Officer. Prior to joining Coronado, Mr. Gemignani was Executive Vice President, Chief Operating Officer and Chief Financial Officer of Gentium SpA, a developer of drugs for complications of cancer therapy. Prior to that, Mr. Gemignani held management positions of increasing responsibility at Wyeth, Novartis, and Prudential Financial.

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements.  These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations of the Company's product candidates, as well as the potential role these product candidates may play in the treatment of cancers. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the Company's need for additional capital to fund its clinical development programs, the possibility that the results of clinical trials will not support the Company's claims, the possibility that the Company's development efforts relating to its product candidates will not be successful, the inability to obtain regulatory approval of the Company's product candidates, the Company's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Coronado Biosciences, Inc. Contact:

Gary Gemignani, (212) 332-1666, ggemignani@coronadobiosciences.com




'/>"/>
SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
4. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
5. Neurocrine Biosciences, Inc. Prices Common Stock Offering
6. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
7. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... N.J. , Feb. 12, 2016  Innophos Holdings, Inc. ... and nutritional specialty ingredients, today announced that it will host ... 10:00 am ET to discuss its fourth quarter and full ... --> The press release detailing fourth quarter and full ... after market close. --> ...
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., a ... System ® ("iFuse"), a minimally invasive surgical (MIS) device indicated ... that National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) ... Illinois , Maine , Massachusetts ... , New York , Rhode ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, ... The purpose of these scholarships is to encourage applicants to pursue a degree ... employment within these two parishes. , “We have available jobs in St. Landry ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to ... , As Winston Churchill said, “Those who don’t learn from history ... show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
Breaking Medicine News(10 mins):